Bortezomib has received Food and Drug Administration (FDA) approval for the treatment of multiple myeloma [4], a disease that demonstrates some similarities with PEL, such as the constitutive activation of NF-Kappa B and STAT3. The gene discussed is STAT3; the disease is primary effusion lymphoma.